Refer to the figure to answer the following questions. Insert Text Manufactured by: Ben Venue Laboratories,...

Transcribed Image Text:

Refer to the figure to answer the following questions. Insert Text Manufactured by: Ben Venue Laboratories, Inc. Bedford, OH 44146 Manufactured for: Bedford Laboratories Bedford, OH 44146 Patient Information CARBOplatin for Injection Read this entire leaflet carefully. Keep it for future reference. This information will help you learn more about CARBOplatin for Injection. It cannot, however, cover all the possible warnings or side effects relating to CARBOplatin, and it does not list all of the benefits and risks of CARBOplatin. Your doctor should always be your first choice for detailed information about your medical condition and your treatment. Be sure to ask your doctor about any questions you may have. DOSAGE AND ADMINISTRATION NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin. Single Agent Therapy Carboplatin for injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m IV on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin injection-300 mg/m IV on day 1 every four weeks for six cycles (alternatively see Formula Dosing). Cyclophosphamide 600 mg/m IV on day 1 every four weeks for six cycles. For directions regarding the use and administration of cyclophos- phamide please refer to its package insert. (See CLINICAL STUDIES.) i Another patient with ovarian cancer, who weighs 164 lb and measures 68 in, is to receive carboplatin. What is her BSA (in m)? (Express your answer to the nearest hundredth.) xm2 1.88 What dosage of carboplatin (in mg) will she require? (Express your answer to the nearest whole number.) 677 mg Refer to the figure to answer the following questions. Insert Text Manufactured by: Ben Venue Laboratories, Inc. Bedford, OH 44146 Manufactured for: Bedford Laboratories Bedford, OH 44146 Patient Information CARBOplatin for Injection Read this entire leaflet carefully. Keep it for future reference. This information will help you learn more about CARBOplatin for Injection. It cannot, however, cover all the possible warnings or side effects relating to CARBOplatin, and it does not list all of the benefits and risks of CARBOplatin. Your doctor should always be your first choice for detailed information about your medical condition and your treatment. Be sure to ask your doctor about any questions you may have. DOSAGE AND ADMINISTRATION NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin. Single Agent Therapy Carboplatin for injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m IV on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin injection-300 mg/m IV on day 1 every four weeks for six cycles (alternatively see Formula Dosing). Cyclophosphamide 600 mg/m IV on day 1 every four weeks for six cycles. For directions regarding the use and administration of cyclophos- phamide please refer to its package insert. (See CLINICAL STUDIES.) i Another patient with ovarian cancer, who weighs 164 lb and measures 68 in, is to receive carboplatin. What is her BSA (in m)? (Express your answer to the nearest hundredth.) xm2 1.88 What dosage of carboplatin (in mg) will she require? (Express your answer to the nearest whole number.) 677 mg